| Journal | Chemistry & biodiversity |
| Study Type | Randomized Trial |
| Population | Human participants |
This comprehensive review synthesizes evidence across cannabis medicine’s core domainsโphytochemistry, pharmacology, clinical applications, and regulatory frameworks. For clinicians entering cannabis medicine, it provides a structured foundation for understanding the complexity of whole-plant therapeutics beyond isolated cannabinoids.
This systematic review examines over 500 identified cannabis compounds including cannabinoids, terpenes, flavonoids, and alkaloids across therapeutic domains of chronic pain, epilepsy, oncology, psychiatry, and inflammation. The authors integrate historical use patterns, phytochemical analysis, clinical trial data, and regulatory perspectives to map current evidence. Notable limitations include acknowledgment of dosing uncertainties, long-term safety gaps, and standardization challenges that persist across cannabis medicine. The review emphasizes evidence gaps requiring randomized controlled trials for evidence-based practice advancement.
โThis review accurately captures both the therapeutic promise and clinical challenges I encounter dailyโwe have compelling mechanistic rationale and patient outcomes, yet dosing remains more art than science. The emphasis on standardization and rigorous trial design reflects the field’s maturation toward evidence-based practice.โ
๐ฌ Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan โ
Want to discuss this topic with other patients and caregivers? Join the forum discussion โ
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.